human tyrosinase vaccine

A **human tyrosinase vaccine** is an investigational DNA or viral vector-based vaccine that encodes the gene for **human tyrosinase**, a melanosomal differentiation antigen. The vaccine is designed to induce an immune response against cells expressing tyrosinase, especially malignant melanoma cells. By presenting human tyrosinase to the host immune system, which differs sufficiently from endogenous tyrosinase, the vaccine breaks immune tolerance and triggers both antibody and cellular (primarily CD8+ T cell) responses that can cross-react with tumor cells. The vaccine has been evaluated both in dogs (as ONCEPT, for canine oral melanoma) and humans, typically as plasmid DNA and as recombinant modified vaccinia virus Ankara (MVA-hTyr) vector, targeting melanoma as a primary indication. The mechanism involves stimulating immune recognition of human tyrosinase presented by tumor (melanoma) cells, leveraging xenogeneic immunization for enhanced antitumor activity[1][3][4][5].

Brand names

ONCEPT Canine Melanoma VaccineDNA

Other names

human tyrosinase vaccinexenogeneic tyrosinase DNA vaccinemodified vaccinia virus Ankara-human tyrosinase vaccine